NeuraxisNRXS
Market Cap: $20.2M
About: Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Employees: 19
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
33% more capital invested
Capital invested by funds: $233K [Q1] → $308K (+$75.7K) [Q2]
25% more funds holding
Funds holding: 8 [Q1] → 10 (+2) [Q2]
0.26% more ownership
Funds ownership: 1.41% [Q1] → 1.67% (+0.26%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for NRXS.
Financial journalist opinion
Based on 4 articles about NRXS published over the past 30 days